2125-Mel-301- A Randomized Phase 3 Comparison Of Imo-2125 With Ipilimumab Versus Ipilimumab Alone In Subjects With Anti-Pd-1 Refractory Melanoma
Posted Date: May 15, 2019
- Investigator: Rekha Chaudhary
- Specialties: Cancer, Oncology
- Type of Study: Drug
The goal of this study is to compare the efficacy (measured by OS and ORR) of intratumoral IMO-2125 in combination with ipilimumab versus ipilimumab alone.
To Be Eligible: Confirmed Diagnosis Of Metastatic Melanoma, >18 Years Of Age, Nonpregnant/Nonbreastfeeding, No Active Autoimmune Disease Or Another Malignancy Within 3 Yuers.
2125-Mel-301, Melanoma, Phase Iii, Skin Cancer
For More Information:
Uc Cancer Institute